Literature DB >> 3004712

Cross-resistance to intercalating agents in an epipodophyllotoxin-resistant Chinese hamster ovary cell line: evidence for a common intracellular target.

B Glisson, R Gupta, P Hodges, W Ross.   

Abstract

Several intercalating agents, as well as the epipodophyllotoxins, appear to effect DNA damage through their interaction with type II DNA topoisomerases. However, the relationship of this phenomenon to anti-tumor activity remains unproven. Our studies with an epipodophyllotoxin-resistant cell line not only provide additional evidence that the enzyme is a multidrug target but also serve to implicate it as a mediator of cytotoxic effect. When compared to wild-type cells, the epipodophyllotoxin-resistant Chinese hamster ovary cell line, VpmR-5, exhibits cross-resistance to both the cytotoxic and DNA cleavage activities of 4',9-acridinylaminomethanesulfon-m-anisidide, mitoxantrone, and Adriamycin. Steady-state concentrations of radiolabeled-4',9-acridinylaminomethanesulfon-m-anisidide and daunomycin are identical in both cell lines. Sharp plateaus in the VpmR-5 dose-response curves for Adriamycin-induced DNA strand breaks and cytotoxicity appear to be related to interference with type II topoisomerase-mediated cleavage of DNA at high concentrations of the intercalator. These data support a direct role for DNA strand scission in cell death and also suggest that multidrug resistance may be acquired by a qualitative change in type II topoisomerase that alters interaction of drug with the enzyme or enzyme-DNA complex.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3004712

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Dissociation of cytotoxicity and DNA cleavage activity induced by topoisomerase II-reactive intercalating agents in hamster-human somatic cell hybrids.

Authors:  B S Glisson; A M Killary; P Merta; W E Ross; J Siciliano; M J Siciliano
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  Resistance to cytostatic drugs at the cellular level.

Authors:  C P Vendrik; J J Bergers; W H De Jong; P A Steerenberg
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 3.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

Review 4.  Topoisomerases, new targets in cancer chemotherapy.

Authors:  J G Zijlstra; S de Jong; E G de Vries; N H Mulder
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

5.  Topoisomerase inhibitors can selectively interfere with different stages of simian virus 40 DNA replication.

Authors:  R M Snapka
Journal:  Mol Cell Biol       Date:  1986-12       Impact factor: 4.272

6.  Expressions of resistance and cross-resistance in teniposide-resistant L1210 cells.

Authors:  D Roberts; T Lee; E Parganas; L Wiggins; J Yalowich; R Ashmun
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  Ability of four potential topoisomerase II inhibitors to enhance the cytotoxicity of cis-diamminedichloroplatinum (II) in Chinese hamster ovary cells and in an epipodophyllotoxin-resistant subline.

Authors:  J P Eder; B A Teicher; S A Holden; L Senator; K N Cathcart; L E Schnipper
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

8.  Overproduction of topoisomerase II in an ataxia telangiectasia fibroblast cell line: comparison with a topoisomerase II-overproducing hamster cell mutant.

Authors:  S M Davies; A L Harris; I D Hickson
Journal:  Nucleic Acids Res       Date:  1989-02-25       Impact factor: 16.971

Review 9.  Modulation of tumor cell response to chemotherapy by the organ environment.

Authors:  I J Fidler; C Wilmanns; A Staroselsky; R Radinsky; Z Dong; D Fan
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

Review 10.  The clinical pharmacology of etoposide and teniposide.

Authors:  P I Clark; M L Slevin
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.